WALSH COLIN
SEC Form 4 insider trading activity
WALSH COLIN has filed 2 SEC Form 4 filings (54 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 28, 2026.
On the most recent filing, WALSH COLIN is listed as Director at Attovia Therapeutics, Inc. Inside the rolling window, WALSH COLIN reported 2 open-market purchases totaling $10.3M in ATTO and 1 open-market sale totaling $2.2M in ATTO. The largest disclosed transaction in the window is a purchase of 500,000 ATTO shares on Aug 6, 2026, worth $8.5M.
Companies traded
Other insiders at ATTO
Insider Buying
$10.3M
reported purchases (SEC code P)
Insider Selling
$2.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has WALSH COLIN made?
WALSH COLIN has filed 2 SEC Form 4 filings (54 transaction rows) across 1 company since 2026.
Which companies does WALSH COLIN trade?
WALSH COLIN has filed SEC Form 4 disclosures for 1 company, including ATTO.
When was WALSH COLIN's most recent SEC Form 4 filing?
WALSH COLIN's most recent SEC Form 4 filing on Tracefour is dated Aug 28, 2026.
What is WALSH COLIN's total buy and sell value in the current window?
Inside the rolling retention window, WALSH COLIN bought $10.3M and sold $2.2M based on SEC Form 4 filings.
What was WALSH COLIN's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 500,000 ATTO shares on 2026-08-06, worth $8.5M, per SEC Form 4 filings.